The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2021 | Highlights of ICML 2021
Franco Cavalli, MD, FRCP, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, provides an overview of the topics discussed at the 2021 International Conference on Malignant Lymphoma, which included keynote lectures on future strategies in treating chronic lymphocytic leukemia (CLL), advances in liquid biopsies, immunotherapy in lymphoma management, and the tumor microenvironment in lymphoma. Additional topics discussed include the role of artificial intelligence in diagnosis and clinical trials, as well as workshops dedicated to radiotherapy. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
